Fri, August 4, 2023
Thu, August 3, 2023
Wed, August 2, 2023

Serge Belanger Reiterated (BCRX) at Strong Buy with Decreased Target to $12 on, Aug 3rd, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-12-on-aug-3rd-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Serge Belanger of Needham, Reiterated "BioCryst Pharmaceuticals, Inc." (BCRX) at Strong Buy with Decreased Target from $14 to $12 on, Aug 3rd, 2023.

Serge has made no other calls on BCRX in the last 4 months.



There are 3 other peers that have a rating on BCRX. Out of the 3 peers that are also analyzing BCRX, 1 agrees with Serge's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Reiterated at Hold and Held Target at $9 on, Thursday, May 4th, 2023


These are the ratings of the 2 analyists that currently disagree with Serge


  • Tazeen Ahmad of "B of A Securities" Upgraded from Hold to Strong Buy and Held Target at $10 on, Thursday, July 13th, 2023
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Decreased Target to $10 on, Thursday, April 20th, 2023

Publication Contributing Sources